Insights
Insights From Our Experts
Articles
CASE STUDY: Transforming Clinical Trials with EVERSANA
Modernizing Clinical Trials to Accelerate Access Clinical trials are essential for bringing life-changing therapies to market, yet traditional models often present significant barriers for both participants and trial sites. A leading pharmaceutical manufacturer partnered with EVERSANA…
Beyond Clinical Trials: Real-World Evidence Illuminates the Value of First-Line CDK4/6i in Metastatic Breast Cancer
While randomized controlled trials (RCTs) have been instrumental in establishing new standards of care, a comprehensive understanding of treatment effectiveness requires insights from real-world evidence (RWE). This is particularly true in the evolving landscape of hormone…
Escaping the Chronic Microcap Trap: How Launching Alone Is the Only Option for Growth
As C-suite leaders in pharma wrestle with the pros and cons of launching alone, licensing or partnering with another company to launch their product, one factor they must consider is the impact their decision will have…
Case Study: Increasing Product Adoption Rate through EVERSANA’s Digital Hub Portal
Problem: Our client launched a new product in the U.S. market, but initial adoption rates were disappointingly low. Physicians, who were eager to incorporate this innovative product into their practice, hesitated to prescribe from the complexity…
Evaluating Talazoparib Plus Enzalutamide Against Standard of Care Therapies in Metastatic Castration-Resistant Prostate Cancer: A Matching-Adjusted Indirect Comparison
Posted by
Imtiaz Samjoo , Anja Haltner, MSc , Samantha Craigie , Sarah Walsh on March 27, 20253/27/25
Metastatic castration-resistant prostate cancer (mCRPC) is an incurable condition associated with poor prognosis and reduced quality of life. Historically, treatment options were limited, and despite recent advancements, the five-year survival rate for metastatic prostate cancer remains…
Optimizing Specialty Pharmacy Networks: A Best-in-Class Approach for Rare Disease Therapies
For manufacturers of rare disease therapies, selecting the right specialty pharmacy model is a crucial decision that directly impacts patient access, adherence and overall brand success. An exclusive specialty pharmacy model offers distinct advantages, including streamlined…
The End of the Blockbuster: Adapting to a New Pharmaceutical Landscape With a New Commercialization Model
Traditional commercialization strategies that once fueled massive growth and profitability are no longer viable in today’s complex and competitive market. High SG&A costs without resulting revenue, patent cliffs, rising patient acquisition costs, convoluted supply chain management,…
EVERSANA Wins AI Excellence Award for 4th Straight Year, Building on Legacy of Innovation
Company recognized in 2025 for AI-Powered HCP Panels Used for Sales Representative Training Innovation is in the lifeblood of EVERSANA. And so, when the 2025 AI Excellence Awards winners were announced, it was not surprising that…
Capital Efficient Commercialization: A New Model for Success
In today’s fiscal environment, efficient capital allocation is crucial for success. Biopharma companies can take advantage of new approaches to commercialization to dramatically reduce the capital burden to launch their products. Building Your Own Commercial Infrastructure…
Boosting Pharma Efficiency: A New Model for Asset Value Retention
In the pharmaceutical industry, maintaining asset value is challenging. Traditionally, companies either licensed their products or built their own commercial setup, each option with its own risks. But what if there were a powerful alternative that…